Mode
Text Size
Log in / Sign up
Phase 2 Completed N=169 Randomized Triple-blind Treatment

To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee

Source: ClinicalTrials.gov NCT01160822 ↗
Enrolled (actual)
169
Serious AEs
5.9%
Results posted
Aug 2012
Primary outcomePrimary: Part A: Number of Participants With Intolerance Events — 0; 0; 0; 0 participants

Summary

The purpose of this study was to determine whether, in patients with mild to moderate knee osteoarthritis, canakinumab is safe and tolerable when injected intra-articularly.

Outcome Measures

OutcomeResultp-value
PRIMARY
Part A: Number of Participants With Intolerance Events
0; 0; 0; 0
PRIMARY
Part B: Change From Baseline to Day 4 in Pain Using 100 mm Visual Analog Scale (VAS)
-26.7; -26.5; -27.6
PRIMARY
Part B: Change From Baseline to Week 4 in Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale
-3.5; -4.0; -4.5
SECONDARY
Part B: Change From Baseline in Pain Using 100 mm Visual Analog Scale (VAS)
-25.6; -31.1; -36.1; -26.2; -30.9; -33.0
SECONDARY
Part B: Percentage of Responders in the Pain 100 mm Visual Analog Scale (VAS)
50.0; 43.2; 47.9; 40.5; 45.5; 56.3
SECONDARY
Part B: Change From Baseline in WOMAC Pain, Stiffness and Physical Function Subscales
-3.7; -4.2; -4.6; -3.2; -4.5; -4.0
SECONDARY
Part B: Proportion of Participants Who Used Rescue Analgesic During Study
0.27; 0.30; 0.19; 0.45; 0.47; 0.23
SECONDARY
Patient's Global Assessment of Response to Treatment on Day 4
6; 8; 4; 14; 16; 20
SECONDARY
Patient's Global Assessment of Response to Treatment at Week 2
5; 6; 11; 12; 16; 19
SECONDARY
Patient's Global Assessment of Response to Treatment at Week 4
5; 6; 9; 15; 16; 18
SECONDARY
Patient's Global Assessment of Response to Treatment at Week 8
5; 5; 10; 9; 19; 18
SECONDARY
Patient's Global Assessment of Response to Treatment at Week 12
4; 8; 7; 12; 13; 15
SECONDARY
Part B: Physician's Global Assessment of Response to Treatment at Day 4
8; 7; 6; 11; 18; 21
SECONDARY
Part B: Physician's Global Assessment of Response to Treatment at Week 2
7; 5; 15; 15; 20; 20
SECONDARY
Part B: Physician's Global Assessment of Response to Treatment at Week 4
4; 5; 9; 15; 20; 21
SECONDARY
Part B: Physician's Global Assessment of Response to Treatment at Week 8
5; 3; 9; 13; 22; 16
SECONDARY
Part B: Physician's Global Assessment of Response to Treatment at Week 12
5; 7; 10; 13; 16; 15
SECONDARY
Maximum Observed Plasma Concentration of Canakinumab (Cmax)
23.0; 34.8; 65.5; 77.8
SECONDARY
Time to Reach the Maximum Observed Plasma Concentration of Canakinumab (Tmax)
96.2; 86.7; 144; 95.9
SECONDARY
Area Under the Concentration Time Curve up to the Last Measurable Concentration (AUClast)
16900; 30700; 56100; 71900
SECONDARY
Area Under the Concentration Time Curve From Time Zero to Infinity AUC(0-inf)
16900; 32400; 49300; 78300
SECONDARY
Terminal Phase Half-life (t1/2) of Canakinumab
539; 578; 474; 736
SECONDARY
Apparent Clearance of Canakinumab From Plasma (CL/F)
9.58; 9.66; 13.3; 8.65
SECONDARY
Apparent Volume of Distribution During Terminal Phase (Vz/F)
7320; 8060; 8930; 8910

Eligibility Criteria

Inclusion Criteria

  • Written informed consent must be obtained before any assessment is performed.
  • Male and female patients aged 40 - 80 years (inclusive).
  • Diagnosis of knee osteoarthritis
  • Radiographic evidence of tibiofemoral compartment osteoarthritis
  • Pain in the knee during the last 24 hours.The patients should also have had pain in the affected knee on most days over the last month.
  • Patients who are willing to discontinue all non-steroidal anti-inflammatory drugs (NSAIDs) or other analgesic medication taken for any condition, including their knee pain,
  • Patients who are on stable dose of opioids for at least 1 month before screening can continue to take their opioid at this stable dose throughout the study.
  • Patients must also be willing to abstain from any intra-articular or peri-articular injections to the knee or surgery during the treatment period
  • Patients who, if they are currently taking aspirin (325 mg/day or less; as anti-coagulants), are willing to remain on a stable dose one month prior to screening and throughout the study

Exclusion Criteria

  • Subjects with known hypersensitivity to any biological or investigational drugs.
  • Patients with contraindications to knee injections
  • Patients with joint effusion
  • Patients should not have rheumatoid arthritis or any connective tissue like disease
  • Secondary osteoarthritis with history and/or any evidence of the following diseases: septic arthritis, inflammatory joint disease, gout, Paget's disease of the bone, articular fracture, major dysplasias or congenital abnormality, ochronosis, acromegaly, hemochromatosis, Wilson's disease, primary osteochondromatosis, juvenile chronic arthritis with continued activity in adulthood, heritable disorders (e.g. hypermobility). Patients with secondary osteoarthritis following menisectomy or injuries of a collateral or cruciate ligament are not excluded.
  • Presence or history of underlying metabolic, endocrine, hematologic, pulmonary, cardiac, blood, renal, hepatic, infectious, psychiatric or gastrointestinal conditions
  • Evidence of tuberculosis (TB)
  • One of the risk factors for TB such as:
  • Substance abuse (e.g. injection or non-injection)
  • Health-care workers with unprotected exposure to patients who are at high risk of TB
  • Patients with TB disease before the identification and correct airborne precautions of the patient
  • close contact (i.e. share the same air space in a household or other enclosed environment for a prolonged period (days or weeks, not minutes or hours)) with a person with active pulmonary TB disease.
  • Significant medical problems, including but not limited to the following: uncontrolled hypertension,congestive heart failure, uncontrolled diabetes type I and II
  • Subjects with evidence of hepatic or blood coagulation disorders (i.e. hemophilia, etc), anemia, idiopathic thrombocytopenic purpura, or gastrointestinal disorder: severe hepatic disease, history of alcohol and drug abuse; disease of gall bladder and pancreas; active peptic ulceration, gastrointestinal bleeding or history of severe gastro-esophageal reflux disease or severe hiatus hernia; inflammatory bowel disease.
  • Use of any therapeutic protein drug (e.g. anti-tumor necrosis factor alpha (TNFα) antibody)
  • Presence of severe renal function impairment. History of renal trauma, glomerulonephritis, patients with one kidney, or renal failure requiring regular dialysis treatment.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive pregnancy test (serum or urine).
  • Subjects with known contra-indications to naproxen (e.g. heart or circulation problems, history of ulcer disease etc.), analgesics, antipyretics, or NSAIDs.
  • Disease of the spine or other lower extremity joints which may interfere with the assessment of the target joint.
  • Surgery on the knee within the last year
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01160822). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search